What is PVCT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PVCT?

P/E (TTM) is n/a and 52-week range is $0.04 to $0.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PVCT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PVCT?

The company profile lists revenue (TTM) near $460K, net income (TTM) near -$634M, EPS (TTM) near -$0.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Provectus Biopharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Knoxville, Tennessee, US, 420.3M shares outstanding, ISIN US74373P1084 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Provectus Biopharmaceuticals Inc

$PVCT

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. The company is headquartered in Knoxville, Tennessee and currently employs 6 full-time employees. The company went IPO on 2000-04-07. The firm is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Employees

Website

www.provectusbio.com/

IPO

2000-04-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

OTC MARKETS

ISIN

US74373P1084

Headquarters

Knoxville, Tennessee, US

Shares outstanding

420.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

0.03%

Browse other companiesFree AI scores and summaries for more stocks